Navigating Global Clinical Trial Outsourcing: Risk, Strategy & CRO Partnerships in a Changing World

Gain operational clarity on the evolving landscape of clinical trial outsourcing—discover the risk factors, partnership models, and geographic strategies reshaping CRO selection and clinical operations.

1. Heike Schoen, CEO, Loomis International (LinkedIn)
2. 20+ years in clinical operations, global trial strategy, and vendor management
3. Bart Scheerder, Host
4. Authority in European clinical operations and outsourcing trends
5. David Jones, Head of Content, The PBC Group

Recorded live at COG Europe, Amsterdam.

This episode of The COG Review: Building Better Clinical Studies features Heike Schoen, CEO of Loomis International, in a keynote session from COG Europe. The discussion centers on the global shift in clinical trial outsourcing, with a sharp focus on how sponsors and CROs are adapting to rapid changes in regulation, geopolitics, and technological innovation.

Heike Schoen explores the evolution of sponsor–CRO partnerships, from transactional service agreements to nuanced hybrid models, where flexibility and deep therapeutic expertise are essential for success. Practical examples from Novartis–PPD and Moderna–Medidata illustrate both functional service partnerships and the impact of digital, decentralized trials.

Key areas include CRO selection strategies for emerging markets, navigating regulatory changes, and building operational agility in the face of supply chain fragility and geopolitical risk. Insights are tailored for professionals involved in clinical operations best practices, outsourcing decisions, and those seeking to optimize clinical studies through smarter partnerships and technology use.

The session closes with real-world challenges and live audience questions on how to structure outsourcing models, respond to regulatory shifts, and future-proof location choices for clinical trials.

00:03:37 – Global clinical trial outsourcing market growth and drivers

00:04:45 – The rise of hybrid CRO partnerships: strategic alliances vs. modular models

00:06:06 – Digital platforms and AI: boosting operational efficiency in decentralized trials

00:07:00 – CROs must demonstrate deep therapeutic expertise and flexible service models

00:08:15 – Geographic diversification: assessing emerging markets for clinical study optimization

00:10:06 – AI’s impact on CRO value pools: standardization and resource allocation

00:12:09 – Comparative advantages of clinical outsourcing in the US, Asia-Pacific, Europe, Latin America, Africa, and the Middle East

00:14:24 – Geopolitical risks in outsourcing: contingency planning for disruption and instability

00:16:08 – Supply chain fragility and cross-border data management: lessons for clinical operations best practices

00:18:10 – Key drivers for outsourcing strategy: cost pressure, patient diversity, regulatory speed

00:19:49 – Location strategy essentials and what sponsors should expect from CROs

00:24:29 – Guidance for small biotechs on engaging CROs and designing flexible outsourcing models

1. Hybrid CRO partnership models are becoming standard—sponsors should seek partners who can offer both full-service and functional...

Pipeline Strategy: Balancing Science, Feasibility, and ROI in Clinical Development Decisions

What does it take to make confident, cross-functional pipeline decisions that drive approval speed and sustainable value for companies in today’s clinical research landscape?

Moderated by Emily Roberts-Thomson, Development Operations Leader

Featuring:

• Raj Patel, Chief Operating Officer, ReacX Pharmaceuticals

• Nikhil Dube, Lifecycle Management Strategy Lead, Biogen

• Mukhtar Ahmed, Director, Project and Portfolio Strategy, Greenstone Biosciences

Recorded live at COG Bay Area, this candid panel brings together executive decision-makers from biotech and pharma to break down how leaders navigate real-world portfolio strategy. The episode centers on operational and strategic considerations behind advancing programs through clinical development, highlighting the balance between scientific conviction, development feasibility, market opportunity, and the resource reality facing large and small organizations.

Across the discussion, guests confront the hard questions: How do companies form pipeline priorities when there’s no single formula and risk is high? How is cross-functional alignment reached amid competing perspectives from research, clinical, and business stakeholders? What happens when market forces or funding landscapes suddenly shift, and clinical priorities must adapt in real time?

The conversation offers practical takeaways for leadership teams, study managers, and anyone responsible for portfolio and governance in clinical operations. Listeners will hear direct examples and best practices in portfolio rationalization, aligning R&D and commercial goals, preparing for investor scrutiny, and maintaining flexibility as science, funding, and the therapeutic landscape evolve.

00:03:22 – The critical variables in pipeline decision-making: time to approval, cost, risk profile, and investor priorities in smaller companies.

00:04:45 – Defining the three pillars of commercial portfolio review: scientific rigor, development feasibility, and commercial opportunity.

00:06:14 – Smaller company perspectives: building agility with scientific depth, setting translational feasibility as a practical filter.

00:08:02 – Balancing scientific conviction and commercial realities: frameworks for vetting high-risk, high-potential targets and business discipline in early-stage programs.

00:10:12 – When to deprioritize mechanistically elegant targets that lack translational or commercial plausibility.

00:12:00 – How individual leadership mindsets shift from discovery focus to financial pragmatism with career progression.

00:13:28 – The real challenges of cross-functional alignment: gaining buy-in when teams or investors disagree on program value.

00:16:22 – The unpredictable journey: case example where ‘unexpected’ surviving candidates emerge as portfolio winners.

00:17:05 – The influence of investors and boards - how market timing and external conditions force rapid portfolio shifts.

00:19:03 – Best practices in large-company collaboration: integrating collective baselining and focused scenario-building across commercial and scientific domains.

00:21:38 – Running transparent, non-siloed portfolio processes in smaller biotech - connecting scientific and business data, KOL feedback, and investor imperatives to rapid cycle decisions.

1. Successful portfolio prioritization demands a rigorous cross-functional lens -combining scientific rationale, operational feasibility, and realistic assessments of funding and market drivers.
2. Transparent discussions and alignment between R&D, clinical, and commercial functions are critical...

AI Integration in Clinical Outsourcing: Real-World Applications and Next Steps

Discover actionable guidance for integrating AI into clinical trial outsourcing, with a focus on operational efficiency, quality, and oversight from an experienced biotech leader.

Featuring:

Paulius Ojeras, Head of Clinical Operations, Perceive Biotherapeutics (LinkedIn), keynote speaker at COG Bay Area

Recorded live at COG Bay Area, this session features an in-depth presentation from Paulius Ojeras, who brings more than 18 years directing clinical programs in biotech and CRO environments. With a candid, technical perspective, he explores the evolving adoption of AI agents and automation in clinical operations - cutting through industry hype to share what’s working, where the risks lie, and how to implement with minimal disruption.

Paulius Ojeras addresses the practical realities of AI adoption, from early-stage automation through to “agentic AI” capable of acting as operational teammates. He details the case study of deploying AI for Trial Master File (TMF) management at Perceive Biotherapeutics, outlining the specific gains in error reduction, scalability, and process speed. The discussion goes beyond technology, offering a framework for selecting solutions, evaluating vendors, and anchoring AI initiatives in robust human oversight and process redesign.

This episode is tailored for clinical operations leaders, vendor managers, and outsourcing strategists seeking a best-practice, risk-mitigated approach to AI - filled with hard-won lessons, practical questions for suppliers, and clear indicators of what “good” looks like in this emerging space.

00:02:37 – The ‘AIQ’ (Augmented Intelligence Coefficient): Why most clinical operations teams score near zero today - and what that means for competitive advantage.

00:04:53 – The five levels of AI in clinical trials: From basic automation to fully autonomous agents.

00:06:28 – “Agentic AI” explained: Where AI can become a real teammate, not just a tool, and which activities are best suited for this shift.

00:09:51 – A live case study: How Perceive Biotherapeutics integrated AI teammates into TMF management, what triggered the decision, and how results compared with traditional CRO models.

00:13:02 – AI vs. human performance: How AI reduced TMF filing errors by 25% compared to QC-checked human work, with clear examples of operational improvements.

00:15:10 – Real-time quality by design: Automated document reconciliation, instant issue flagging, and the move away from labor-intensive QC.

00:18:06 – Key vendor selection criteria: Questions to ask, red flags to watch for, and why 95% of AI companies may not survive.

00:21:26 – Consistency, transparency, and validation: Guardrails for ensuring reliability and compliance in regulated trial environments.

00:25:05 – Change management and team education: Why AI literacy, prompt engineering, and cross-functional buy-in matter for sustainable implementation.

00:26:47 – The end game: How AI should amplify - not complicate - operations, freeing teams to focus on patient and protocol quality.

1. Think beyond automation - strategically redesign processes for “agentic” AI, ensuring humans focus on oversight and exception handling, not repetitive tasks.
2. Assess vendors the way you’d assess a new CRO: demand proof of real deployment, robust oversight, and clear accountability, not just a slick demo.
3. Invest in AI literacy across your team - garbage in means garbage out, so prompt design and...